Clotam enhances anti-proliferative effect of vincristine in Ewing sarcoma cells
- 165 Downloads
Current therapeutic strategies used in Ewing sarcoma (ES) especially for relapsed patients have resulted in modest improvements in survival over the past 20 years. Combination therapeutic approach presents as an alternative to overcoming drug resistance in metastatic ES. This study evaluated the effect of Clotam (tolfenamic acid or TA), a small molecule and inhibitor of Specificity protein1 (Sp1) and survivin for sensitizing ES cell lines to chemotherapeutic agent, vincristine (VCR). ES cells (CHLA-9 and TC-32) were treated with TA or VCR or TA + VCR (combination), and cell viability was assessed after 24/48/72 h. Effect of TA or VCR or TA + VCR treatment on cell cycle arrest and apoptosis were evaluated using propidium iodide, cell cycle assay and Annexin V flow cytometry respectively. The apoptosis markers, caspase 3/7 (activity levels) and cleaved-PARP (protein expression) were measured. Cardiomyocytes, H9C2 were used as non-malignant cells. While, all treatments caused time- and dose-dependent inhibition of cell viability, interestingly, combination treatment caused significantly higher response (~ 80% inhibition, p < 0.05). Cell viability inhibition was accompanied by inhibition of Sp1 and Survivin. TA + VCR treatment significantly (p < 0.05) increased caspase 3/7 activity which strongly correlated with upregulated c-PARP level and Annexin V staining. Cell cycle arrest was observed at G0/G1 (TA) or G2/M (VCR and TA + VCR). All treatments did not cause cytotoxicity in H9C2 cells. These results suggest that TA could enhance the anti-cancer activity of VCR in ES cells. Therefore, TA + VCR combination could be further tested to develop as safe/effective therapeutic strategy for treating ES.
KeywordsEwing sarcoma Tolfenamic acid Vincristine Sp1 Survivin
This work is partially supported by HyundaiHopeOnWheels Young Investigator Grant awarded to AR. RB is supported by National Institute for Minority Health and Health Disparities (Grant # 2U54 MD006882-06) and SR is supported by a grant from the Rutledge Cancer Foundation. Authors thank Childhood Cancer Repository at the Texas Tech University Health Sciences Center in Lubbock, TX for providing Ewing sarcoma cell lines.
Compliance with Ethical Standards
Conflict of interest
All authors declare that they have no conflict of interest.
- 3.Mascarenhas L, Felgenhauer JL, Bond MC et al (2016) Pilot study of adding vincristine, topotecan, and cyclophosphamide to interval-compressed chemotherapy in newly diagnosed patients with localized Ewing sarcoma: a report from the Children’s Oncology Group. Pediatr Blood Cancer 63:493–498CrossRefGoogle Scholar
- 8.Yap BS, Baker LH, Sinkovics JG et al (1980) Cyclophosphamide, vincristine, adriamycin, and DTIC (CYVADIC) combination chemotherapy for the treatment of advanced sarcomas. Cancer Treat Rep 64:93–98Google Scholar
- 9.Breitfeld PP, Lyden E, Raney RB et al (2001) Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group. J Pediatr Hematol Oncol 23:225–233CrossRefGoogle Scholar
- 10.Thompson J, George EO, Poquette CA et al (1999) Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts. Clin Cancer Res 5:3617–3631Google Scholar
- 11.Simsek T, Uner M, Trak B, Erman O, Zorlu GC (1998) Toxicity of chemotherapeutical protocols in the treatment of uterine sarcomas (vincristine, actinomycin D, cyclophosphamide VAC versus ifosfamide). Eur J Gynaecol Oncol 19:405–407Google Scholar
- 13.Bacci G, Picci P, Ferrari S et al (1998) Neoadjuvant chemotherapy for Ewing’s sarcoma of bone: no benefit observed after adding ifosfamide and etoposide to vincristine, actinomycin, cyclophosphamide, and doxorubicin in the maintenance phase—results of two sequential studies. Cancer 82:1174–1183CrossRefGoogle Scholar
- 18.Basha R, Connelly SF, Sankpal UT et al (2016) Small molecule tolfenamic acid and dietary spice curcumin treatment enhances antiproliferative effect in pancreatic cancer cells via suppressing Sp1, disrupting NF-kB translocation to nucleus and cell cycle phase distribution. J Nutr Biochem 31:77–87CrossRefGoogle Scholar
- 21.Chang JW, Kang SU, Choi JW et al (2014) Tolfenamic acid induces apoptosis and growth inhibition in anaplastic thyroid cancer: Involvement of nonsteroidal anti-inflammatory drug-activated gene-1 expression and intracellular reactive oxygen species generation. Free Radic Biol Med 67:115–130CrossRefGoogle Scholar
- 23.Vaitkus A, Pauza V (2002) [Effectiveness of tolfenamic acid in the prevention of migraine]. Medicina (Kaunas) 38:296–303Google Scholar
- 26.Dittus C, Grover N, Ellsworth S, Tan X, Park SI (2018) Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis. Leuk Lymphoma 59:2121–2127CrossRefGoogle Scholar
- 31.Mora E, Smith EM, Donohoe C, Hertz DL (2016) Vincristine-induced peripheral neuropathy in pediatric cancer patients. Am J Cancer Res 6:2416–2430Google Scholar
- 35.Kappler M, Kotzsch M, Bartel F et al (2003) Elevated expression level of survivin protein in soft-tissue sarcomas is a strong independent predictor of survival. Clin Cancer Res 9:1098–1104Google Scholar
- 39.Souza PS, Vasconcelos FC, De Souza Reis FR, Nestal De Moraes G, Maia RC (2011) P-glycoprotein and survivin simultaneously regulate vincristine-induced apoptosis in chronic myeloid leukemia cells. Int J Oncol 39:925–933Google Scholar